Plasma miR-758-3p demonstrated clinical relevance as a biomarker for progression of obesity to MetS, so our subsequent analysis was to investigate if miR-758-3p can target and control expression of cholesterol efflux regulatory protein/ATP-binding cassette transporter (CERP/ABCA1); its predicted target. This evidence concerns the gene ABCA4 and metabolic syndrome.